Research by the Tufts Center for the Study of Drug Development has found that Thermo Fisher Scientific's Accelerator Drug Development 360° CDMO and CRO solutions can reduce drug development timelines by up to nearly three years.
The integrated services are estimated to reduce time to commercialisation by steamlining the process.
In the past, drug developers have had to rely on multiple supplier partners for bioprocessing, clinical development, clinical supply and manufacturing solutions, which can both complicate and slow the development process significantly.
By using the Accelerator scheme, however, harnesses a centralised approach that promotes efficiency, effective communication and a reduction in delays.
The Tufts CSDD study has demonstrated that working with an integrated CDMO or CRO partner can help streamline the process.
Accelerator Drug Development provides a customizable suite of manufacturing, clinical research and clinical supply chain services at every stage of development.
To date, more than 120 biotech and biopharma companies have worked with Thermo Fisher across its integrated CDMO and CRO solutions on more than 350 protocols across therapeutic areas, small molecule, large molecule and advanced therapies.
“This new study highlights the opportunity to deliver safe new medicines to patients significantly faster,” said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific.
“Through Accelerator Drug Development, we are well positioned to bring customisable, end-to-end solutions and world-leading expertise to our customers, and we’re proud of the capabilities we’ve built to meet customer and patient needs.”
Interestingly, those that used integrated services from Phase I through to Phase III could reduce drug development times by up to 34 months.
Researchers also found that integrated CRO/CDMO services can generate up to $63m in net financial benefits for drug sponsors — which is up to 113x the initial investment.
In considering multiple scenarios across phases of drug development and different levels of investment in integrated services, researchers found demonstrable time savings and ROI across the board, reflecting the benefits of integration, such as cross-functional program coordination, collaboration, oversight, planning and communication.
“This study,” the authors wrote, “demonstrates that integration of services across development and manufacturing functions can yield substantial benefits to drug sponsors in the form of shorter clinical development durations. The findings from this study provide a compelling case for drug sponsors to consider single-vendor integrated CDMO and CRO solutions as a means of addressing operational inefficiencies.”
